What do systematic reviews say?

Pregabalin vs active comparators

Pregabalin showed no clear difference in 50% or greater reduction in seizurefrequency compared with active comparators (low certainty).

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 1.03 [0.85, 1.25]
  3 studies · 1286 participants
  Low
• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 1.6 [1.17, 2.19]
  3 studies · 1286 participants
  Very low
• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 0.67 [0.62, 0.74]
  3 studies · 1286 participants
  Moderate

Pregabalin vs active comparators

It is very uncertain whether pregabalin changes seizure freedom compared with active comparators (very low certainty).

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 0.59 [0.37, 0.95]
  2 studies · 802 participants
  Very low

Pregabalin vs active comparators

Pregabalin showed no clear difference in treatment withdrawal for any reason compared with active comparators (low certainty).

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  RR 0.93 [0.76, 1.13]
  3 studies · 1286 participants
  Low

Pregabalin vs active comparators

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  1.04 [0.73, 1.48]
  3 studies · 1286 participants
  Low

Pregabalin vs active comparators

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  1.72 [0.54, 5.55]
  1 study · 293 participants
  Low

Pregabalin vs active comparators

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  1.64 [0.85, 3.16]
  3 studies · 1286 participants
  Low

Pregabalin vs active comparators

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  1.72 [0.77, 3.83]
  1 study · 293 participants
  Low

Pregabalin vs active comparators

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  0.83 [0.41, 1.65]
  3 studies · 1286 participants
  Very low

Pregabalin vs active comparators

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  0.2 [0.04, 1.01]
  1 study · 509 participants
  Very low

Pregabalin vs active comparators

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  1.16 [0.88, 1.53]
  3 studies · 1286 participants
  Low

Pregabalin vs active comparators

• Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  2.87 [0.94, 8.75]
  3 studies · 1286 participants
  Low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

It is very uncertain whether interventions (vitamin B1, mefenamic acid, tranexamic acid) changes side effects: gastrointestinal disturbances (diarrhoea, lower… compared with placebo or active comparators (desmopressin, sodium diclofenac,… (very low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 4.69 [1.2, 18.44]
  1 study · 38 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 110 participants
  Low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 290 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Interventions (vitamin B1, mefenamic acid, tranexamic acid) showed no clear difference in side effects: headache compared with placebo or active comparators (desmopressin, sodium diclofenac,… (low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 0.58 [0.18, 1.92]
  1 study · 100 participants
  Low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Interventions (vitamin B1, mefenamic acid, tranexamic acid) showed no clear difference in side effects: vomiting compared with placebo or active comparators (desmopressin, sodium diclofenac,… (low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 0.74 [0.25, 2.18]
  1 study · 100 participants
  Low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 participants
  GRADE not reported